clinicaltrialsarena16h
Gilead’s Livdelzi shows promise in PBC clinical trial
Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
The Pharma Letter2d
Gilead’s Livdelzi reduced pruritus severity in PBC participants
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...
Morningstar3d
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch – Gilead Sciences, Inc. (Nasdaq: GILD)today ...
Investing3d
Livdelzi shows promise in PBC treatment study
Gilead Sciences, Inc. (NASDAQ:GILD) today shared interim results from an ongoing Phase 3 ASSURE study, demonstrating that 81% of primary biliary cholangitis (PBC) patients treated with Livdelzi ...
Stockhouse3d
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch – Gilead Sciences, Inc. (Nasdaq: GILD)today announced data ...
Mena FN6h
Five Top Heart Health Stocks To Buy Heading Into 2025
This includes building on the momentum from the U.S. launch of Livdelzi for primary biliary cholangitis and preparing for the ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite ...
Business Wire3d
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
ASSURE (NCT03301506) is an ongoing, open-label, study evaluating the long-term efficacy and safety of Livdelzi. ASSURE is enrolling adults with PBC who previously participated in a study of ...